加尔坎祖马布补充剂在耐火集群头痛中. 一个案例系列
Georgios Karagiorgis1,2, Savvas Christofilos1,3, Christina Deligianni1,4
1First Department of Neurology, Aeginitio Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Pain management
|November 19, 2024
概括
作为CGRP抗体的Galcanezumab在一组不耐药患者中显著减少了每周的集群头痛发作和症状治疗日. 这种附加疗法对难以治疗的集群头痛病例显示出前景.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 集群头痛 (CH) 是一种衰弱的神经系统疾病,有效的预防治疗方法有限.
- 现有的CH治疗方法,特别是耐火病例,往往缺乏基于机制的特异性.
- 在之前的试验中,Galcanezumab是一种单克隆抗体,向色素基因相关 (CGRP),在偶发性CH中表现出有效性,但在慢性CH中没有.
研究的目的:
- 评估加尔坎祖马布作为耐火集群头痛患者的辅助疗法的疗效和安全性.
- 评估加尔坎祖马布对每周头痛发作频率和需要症状治疗的影响.
主要方法:
- 一系列病例涉及11名患有耐火性集群头痛的患者 (5例插曲性,6例慢性),他们接受了加尔坎祖马布 (每月120-360毫克) 3个月.
- 所有参与者以前至少有三次预防性治疗失败,并接受过桥梁治疗 (口服类固醇或尾神经阻塞).
- 通过每周CH攻击和每周需要症状治疗的日数的变化来衡量有效性.
主要成果:
- 3个月后,平均每周CH发作 (从16.0到1.8,p=0.002) 和每周症状治疗日数 (从6.5到1.8,p=0.001) 显著减少.
- 两名患有慢性心血管疾病的患者没有经历过加尔坎祖马布的攻击减少.
- 在研究期间没有报告任何严重不良事件.
结论:
- 补充的加尔坎祖马布治疗在一组耐火集群头痛患者中显著有效降低头痛负担.
- 这些发现与其他现实数据相一致,表明加尔卡内祖马布可能是耐火性CH的有价值的附加治疗选择.
- 需要进一步的研究,以充分理解加尔坎祖马布在治疗耐标准治疗的慢性集群头痛中的作用.
相关概念视频
01:28Angle Closure Glaucoma: Treatment
438
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
438
01:27Open Angle Glaucoma: Treatment
393
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
393